Martin S & his pal's main argument seems to be around the dropout rates skewing things. Blarca had 64% of dosed patients complete vs 74% placebo. Donnanemab (EMA approved) had 75% complete vs 80% placebo. Therefore yes blarca a little more bad but clearly dropouts are normal, it's also normal for dosed to drop out more than placebo there are various stats processes to try and counter for this. Some indications such as shizo have dropouts of around 50%. The dropouts cannot explain away blarca being significantly better than the MABS such as Donnanemab in terms of efficacy vs placebo and of course much safer.
Market Data 
Markets 
AI
